Therapeutic Asset Ratings
766 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Zirconium Zr 89-Dfo-Ys5
Urinary Bladder Neoplasm
Robert Flavell, MD, PhD
P1
CC
(43)
Zirconium Zr 89-Dfo-Ys5
Nerve Sheath Neoplasm
Robert Flavell, MD, PhD
P1
CC
(43)
Zirconium Zr 89-Dfo-Ys5
Neoplasm
Robert Flavell, MD, PhD
P1
CC
(43)
[68ga] mdm2/mdmx peptide
MDM2/MDMX Gene Mutation
Peking University Cancer Hospital & Institute
Early P1
CC
(43)
[68ga] mdm2/mdmx peptide
Nuclear Medicine
Peking University Cancer Hospital & Institute
Early P1
CC
(43)
[68ga] mdm2/mdmx peptide
Positron Emission Tomography Imaing
Peking University Cancer Hospital & Institute
Early P1
CC
(43)
68ga-nodaga-sna009
GPA33
SmartNuclide Biopharma
Early P1
CC
(43)
Copper Cu-64-Dota-Alendronate
Calcinosis
City of Hope Medical Center
Early P1
CC
(43)
[177lu]lu-dpi-4452
Colorectal Cancer
ITM Oncologics GmbH
P1/2
CC
(43)
[177lu]lu-dpi-4452
Pancreatic Ductal Adenocarcinoma
ITM Oncologics GmbH
P1/2
CC
(43)
[177lu]lu-dpi-4452
Triple-Negative Breast Carcinoma
ITM Oncologics GmbH
P1/2
CC
(43)
[177lu]lu-sn201
Metastatic Malignant Neoplasm
Spago Nanomedical AB
P1/2
CC
(43)
[177lu]lu-sn201
Refractory Malignant Neoplasm
Spago Nanomedical AB
P1/2
CC
(43)
177lu-psma-0057
Castration-Resistant Prostate Carcinoma
Chengdu StarRay Therapeutics Co., Ltd
P1/2
CC
(43)
[203pb]pb-psv359
Head And Neck Cancer
Perspective Therapeutics
P1/2
CC
(43)
[203pb]pb-psv359
Sarcoma
Perspective Therapeutics
P1/2
CC
(43)
[203pb]vmt01
Metastatic Melanoma
Perspective Therapeutics
P1/2
CC
(43)
[212pb]pb-psv359
Head And Neck Cancer
Perspective Therapeutics
P1/2
CC
(43)
[212pb]pb-psv359
Sarcoma
Perspective Therapeutics
P1/2
CC
(43)
[212pb]vmt01
Metastatic Melanoma
Perspective Therapeutics
P1/2
CC
(43)
111in-etn029
Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P1
CC
(41)
[111in]-fpi-2058
Ewing Sarcoma
3B Pharmaceuticals GmbH
P1
CC
(41)
[111in]-fpi-2058
Head And Neck Squamous Cell Carcinoma
3B Pharmaceuticals GmbH
P1
CC
(41)
161Tb-SibuDAB
Castration-Resistant Prostate Carcinoma
University Hospital, Basel, Switzerland
P1
CC
(41)
177lu-dfc413
Soft Tissue Sarcoma
Novartis Pharmaceuticals
P1
CC
(41)
Showing 301 to 325 of 766 assets
Previous
Page 13 of 31
Next
